We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.72B
AUM Growth
–
Cap. Flow
+$4.69B
Cap. Flow %
99.51%
Top 10 Hldgs %
37.69%
Holding
127
New
123
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$272M
2
GILD icon
Gilead Sciences
GILD
+$251M
3
BIIB icon
Biogen
BIIB
+$219M
4
MRK icon
Merck
MRK
+$193M
5
VTRS icon
Viatris
VTRS
+$149M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
2 Financials 2.05%
3 Technology 0.14%
4 Utilities 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
101
DELISTED
Achillion Pharmaceuticals
ACHN
$4.46M 0.09%
+545,000
New +$4.16M
CBST
102
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$4.35M 0.09%
+90,000
New +$4.42M
BCR
103
DELISTED
CR Bard Inc.
BCR
$4.13M 0.09%
+38,000
New +$3.95M
ZTS icon
104
Zoetis
ZTS
$32.5B
$4.07M 0.09%
+131,732
New +$4.27M
CVD
105
DELISTED
COVANCE INC.
CVD
$3.65M 0.08%
+48,000
New +$3.59M
CELGZ
106
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$3.65M 0.08%
+500,000
New +$3.63M
QCOR
107
DELISTED
QUESTCOR PHARMA INC
QCOR
$3.63M 0.08%
+80,000
New +$2.84M
AMRN
108
Amarin Corp
AMRN
$293M
$3.48M 0.07%
+30,000
New +$4.14M
ANTH
109
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.43M 0.07%
+116,594
New +$4.35M
EW icon
110
Edwards Lifesciences
EW
$48.2B
$3.36M 0.07%
+300,000
New +$3.55M
UPI
111
DELISTED
UROPLASTY INC-NEW
UPI
$2.99M 0.06%
+1,443,500
New +$3.31M
DNDN
112
CALL
DELISTED
DENDREON CORPORATION
DNDN
$2.88M 0.06%
+698,900
New +$2.97M
BLRX
113
BioLineRX
BLRX
$12.2M
$2.58M 0.05%
+2,649
New +$2.74M
QLTI
114
DELISTED
QLT Inc
QLTI
$2.47M 0.05%
+563,000
New +$4.54M
ITMN
115
DELISTED
INTERMUNE INC
ITMN
$2.27M 0.05%
+236,000
New +$2.25M
GIVN
116
DELISTED
GIVEN IMAGING LTD
GIVN
$1.68M 0.04%
+120,000
New +$1.82M
ASTX
117
CALL
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$1.03M 0.02%
+250,000
New +$1.34M
AUXL
118
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$998K 0.02%
+60,000
New +$958K
XTNT icon
119
Xtant Medical Holdings
XTNT
$59.7M
$789K 0.02%
+14,620
New +$1.21M
CHDX
120
DELISTED
CHINDEX INTL INC
CHDX
$519K 0.01%
+32,000
New +$471K
MR
121
DELISTED
MINDRAY MED INTL LTD SPONSORED ADR REPSTG CL A
MR
$449K 0.01%
+12,000
New +$474K
ONCT
122
CALL
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$330K 0.01%
+36
New +$277K
DVAX
123
CALL
DELISTED
Dynavax Technologies
DVAX
$275K 0.01%
+25,000
New +$527K
1 2 3 4
5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Amgen: 2,619,400 shares worth $258M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Financials and Technology.

  • OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
  • OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
  • OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.

Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.